CTSO · NASDAQ
Cytosorbents (CTSO) Stock Price & Fundamentals
Cytosorbents (CTSO) closed at $326.03 on Oct 9, 2026, up 0.55% from the previous close of $324.25.
Share price, past year
1Y −16.26%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $326.03 |
| Sep 30, 2026 | $327.20 |
| Aug 31, 2026 | $339.85 |
| Jul 31, 2026 | $341.61 |
| Jun 30, 2026 | $353.14 |
| May 29, 2026 | $354.89 |
| Apr 30, 2026 | $358.63 |
| Mar 31, 2026 | $376.06 |
| Feb 27, 2026 | $376.21 |
| Jan 30, 2026 | $371.68 |
| Dec 31, 2025 | $379.67 |
| Nov 28, 2025 | $371.56 |
| Oct 31, 2025 | $383.39 |
Key statistics
- Market cap
- $20.49B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- $37.22M
- Net income (TTM)
- −$18.21M
- Shares outstanding
- 62.8M
- Dividend yield
- —
- 52-week range
- $323.26 – $397.89
Cytosorbents's market cap is $20.49B, based on a share price of $326.03 and 62.8M shares outstanding as of Jun 30, 2026.
Financials
Cytosorbents reported revenue of $37.06M for fiscal 2025, up 4.12% from fiscal 2024.
Cytosorbents reported a net loss of $8.20M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $37.06M | +4.1% | −$8.20M | −22.1% | −$0.13 | −$12.54M |
| FY2024ended Dec 31, 2024 | $35.60M | +14.5% | −$20.72M | −58.2% | −$0.38 | −$14.71M |
| FY2023ended Dec 31, 2023 | $31.08M | −10.4% | −$29.25M | −94.1% | −$0.65 | −$22.19M |
| FY2022ended Dec 31, 2022 | $34.69M | −19.6% | −$32.81M | −94.6% | −$0.75 | −$34.32M |
| FY2021ended Dec 31, 2021 | $43.17M | +5.3% | −$24.56M | −56.9% | −$0.57 | −$17.65M |
| FY2020ended Dec 31, 2020 | $41.00M | +64.4% | −$7.84M | −19.1% | −$0.20 | −$6.32M |
| FY2019ended Dec 31, 2019 | $24.95M | +10.9% | −$19.27M | −77.2% | −$0.60 | −$17.46M |
| FY2018ended Dec 31, 2018 | $22.50M | +48.5% | −$17.21M | −76.5% | — | −$11.51M |
| FY2017ended Dec 31, 2017 | $15.15M | +59.0% | −$8.46M | −55.8% | — | −$7.45M |
| FY2016ended Dec 31, 2016 | $9.53M | — | −$11.76M | −123.5% | — | −$6.87M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $9.63M | −$4.42M | −$0.07 |
| Q1 FY2026ended Mar 31, 2026 | $8.86M | −$5.13M | −$0.08 |
| Q4 FY2025ended Dec 31, 2025 | $9.23M | −$5.50M | — |
| Q3 FY2025ended Sep 30, 2025 | $9.49M | −$3.17M | −$0.05 |
| Q2 FY2025ended Jun 30, 2025 | $9.62M | $1.95M | $0.03 |
| Q1 FY2025ended Mar 31, 2025 | $8.73M | −$1.48M | −$0.02 |
| Q4 FY2024ended Dec 31, 2024 | $9.15M | −$7.57M | — |
| Q3 FY2024ended Sep 30, 2024 | $8.61M | −$2.77M | −$0.05 |
Company profile
- Name
- Cytosorbents Corp
- Ticker
- CTSO
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Surgical & Medical Instruments & Apparatus
- Headquarters
- 305 College Road East, Princeton, NJ 08540
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001175151
Recent SEC filings
- Sep 23, 2026
- Sep 8, 2026
- Aug 14, 2026
- Aug 7, 2026
- Aug 6, 2026
- Aug 6, 2026
- Jul 6, 2026
- Jun 25, 2026
Frequently asked questions
What is Cytosorbents's stock price?
Cytosorbents (CTSO) closed at $326.03 on Oct 9, 2026, up 0.55% from the previous close of $324.25.
What is Cytosorbents's market cap?
Cytosorbents's market cap is $20.49B, based on a share price of $326.03 and 62.8M shares outstanding as of Jun 30, 2026.
How much revenue does Cytosorbents make?
Cytosorbents reported revenue of $37.06M for fiscal 2025, up 4.12% from fiscal 2024.
Does Cytosorbents pay a dividend?
Cytosorbents's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Cytosorbents Corp's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures